Revolutionizing Gene Therapy Manufacturing: The Pro10™ Platform by Viralgen

A Pro10 Cell Line: Proprietary Mammalian Suspension Technology for Scalable rAAV Production

Viralgen has developed a new technology, Pro10™, which is designed to enhance the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. The Pro10™ cell line is a proprietary mammalian suspension technology that allows for the scalable and robust production of rAAVs, addressing the challenges associated with large-scale manufacturing in AAV gene therapies.

The Pro10™ cell line has been fully characterized and licensed for gene therapy development by various biopharmaceutical companies. These cells have been specifically optimized for rAAV production and have successfully been scaled up to 2000L, showcasing consistent and reproducible cell growth rates. They have demonstrated similar productivity levels in both small and large-scale bioreactors and are capable of producing various AAV serotypes.

At Viralgen, the Pro10™ cells play a critical role in their platform process for manufacturing AAV vectors. This platform process has significantly contributed to the production of innovative gene therapies. For more information about the HEK293 derived animal component-free suspension Pro10™ cell line, access the full PDF detailing its properties and benefits.

Leave a Reply